Stock DNA
Pharmaceuticals & Biotechnology
SEK 2,978 Million (Small Cap)
NA (Loss Making)
NA
0.00%
-0.13
-5.24%
0.76
Revenue and Profits:
Net Sales:
-4 Million
(Quarterly Results - Jun 2025)
Net Profit:
174 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-8.02%
0%
-8.02%
6 Months
-17.81%
0%
-17.81%
1 Year
-22.64%
0%
-22.64%
2 Years
55.76%
0%
55.76%
3 Years
-60.45%
0%
-60.45%
4 Years
-75.58%
0%
-75.58%
5 Years
-79.81%
0%
-79.81%
InDex Pharmaceuticals Holding AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
51.42%
EBIT Growth (5y)
-182.57%
EBIT to Interest (avg)
-66.30
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.20
Sales to Capital Employed (avg)
0.14
Tax Ratio
1.20%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0.61%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.73
EV to EBIT
-57.39
EV to EBITDA
-58.71
EV to Capital Employed
0.68
EV to Sales
103.82
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-1.18%
ROE (Latest)
-1.53%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
-4.00
26.00
-115.38%
Operating Profit (PBDIT) excl Other Income
158.60
-179.70
188.26%
Interest
0.00
82.40
-100.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
173.50
-251.00
169.12%
Operating Profit Margin (Excl OI)
0.00%
-6,919.20%
691.92%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is -115.38% vs 0.00% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 169.12% vs -292.19% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
0.10
0.00
Operating Profit (PBDIT) excl Other Income
-110.00
-38.80
-183.51%
Interest
3.80
19.80
-80.81%
Exceptional Items
-176.90
-532.80
66.80%
Consolidate Net Profit
-228.00
-559.60
59.26%
Operating Profit Margin (Excl OI)
-1,108,000.00%
0.00%
-1,10,800.00%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 59.26% vs -457.93% in Dec 2023
About InDex Pharmaceuticals Holding AB 
InDex Pharmaceuticals Holding AB
Pharmaceuticals & Biotechnology
InDex Pharmaceuticals Holding AB is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company is focused in pharmaceuticals development. The Company's drug candidate is cobitolimod that helps in ulcerative colitis treatment. In addition, the Company develops a platform of patent protected substances, DNA based ImmunoModulatory Sequences (DIMS), that helps in the treatment of various immunological diseases. The Company also offers diagnostic kit DiBiCol, which is a PCR-based method that monitors seven biomarkers specific for ulcerative colitis or Crohn’s disease from a single colonic biopsy. InDex Pharmaceuticals Holding AB operates as a parent for InDex Pharmaceuticals AB and InDex Diagnostics AB. Among the Company's shareholders are SEB Venture Capital, Industrifonden and NeoMed Management.
Company Coordinates 
Company Details
Tomtebodavagen 23 , SOLNA None : 171 65
Registrar Details






